Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 8/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | MAX | P61244 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.35 |
| ▸ | TOP2A | P11388 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085124 | 0.85 | — | — | |
| SCHEMBL10085114 | 0.82 | PIK3R1 (0.38) | NQO2MEN1KMT2A | |
| SCHEMBL793645 | 0.74 | NQO2 (0.43) | NQO2MYCMAXMAPTMEN1 | |
| SCHEMBL14691351 | 0.74 | USP8 (0.30) | — | |
| SCHEMBL793314 | 0.73 | MAP4K4 (0.47) | MAPTMEN1KMT2AKDM4E | |
| SCHEMBL793654 | 0.72 | KDM4E (0.44) | MAPTKMT2AKDM4E | |
| SCHEMBL10085128 | 0.69 | MAPT (0.41) | MAPTMEN1KMT2AKDM4ECASP1 | |
| SCHEMBL10085120 | 0.69 | — | — | |
| SCHEMBL24853579 | 0.68 | TP53 (0.34) | TLR8TLR7MAPTMEN1KMT2A | |
| SCHEMBL12279119 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9716241-B2 | Polycyclic dithiophenes | BASF SE (DE) | 2017-07-25 | — | — | US | disclosed |
| US-9716241-B2 | Polycyclic dithiophenes | BASF SE (DE) | 2017-07-25 | — | — | US | disclosed |
| US-20160104849-A1 | POLYCYCLIC DITHIOPHENES | BASF SE (DE) | 2016-04-14 | — | — | US | disclosed |
| US-20160104849-A1 | POLYCYCLIC DITHIOPHENES | BASF SE (DE) | 2016-04-14 | — | — | US | disclosed |
| US-9233930-B2 | Polycyclic dithiophenes | BASF SE (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233930-B2 | Polycyclic dithiophenes | BASF SE (DE) | 2016-01-12 | — | — | US | disclosed |
| US-8436208-B2 | Substituted oligo- or polythiophenes | BASF SE (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8436208-B2 | Substituted oligo- or polythiophenes | BASF SE (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20120097935-A1 | POLYCYCLIC DITHIOPHENES | BASF SE (DE) | 2012-04-26 | — | — | US | disclosed |
| US-20120071617-A1 | DIKETOPYRROLOPYRROLE POLYMERS FOR USE IN ORGANIC SEMICONDUCTOR DEVICES | BASF SE (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20110062426-A1 | SUBSTITUTED OLIGO- OR POLYTHIOPHENES | BASF SE (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110062426-A1 | SUBSTITUTED OLIGO- OR POLYTHIOPHENES | MRPL38, SLC39A7, SLC39A14 | NQO2 3415/4885MYC 882/4885MAX 845/4885 |
| US-20160104849-A1 | POLYCYCLIC DITHIOPHENES | C1R, C2CD5, CBR3 | NQO2 1324/4885MYC 3240/4885MAX 4657/4885 |
| US-20120097935-A1 | POLYCYCLIC DITHIOPHENES | C1R, IPO5, C2CD5 | NQO2 2564/4885MYC 3387/4885MAX 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.